Synergy Pharmaceuticals Inc.
) currently has no approved products. The company has progressed
well with its pipeline in the last few quarters. SP-333 is one of
the important candidates in Synergy Pharma's pipeline, being
developed for the treatment of inflammatory bowel diseases (IBD).
ACTELION LTD (ALIOF): Get Free Report
FOREST LABS A (FRX): Free Stock Analysis
IRONWOOD PHARMA (IRWD): Free Stock Analysis
SYNERGY PHARMAC (SGYP): Free Stock Analysis
To read this article on Zacks.com click here.
Synergy Pharma intends to move forward its proprietary
next-generation guanylate cyclase-C (GC-C) agonist, SP-333, into
a phase II study for the treatment of opioid-induced constipation
(OIC) by year end. The phase II study (dose-ranging study) will
be evaluating a 4-week regimen of the candidate in adults. The
adults in the study have been taking opioid analgesics for
chronic, non-cancer pain for a minimum of three months.
In the second quarter of 2013, Synergy Pharma successfully
completed a phase I placebo-controlled, dose-escalating,
multiple-dose study on SP-333 in patients with IBD.
Another interesting candidate at Synergy Pharma is plecanatide.
Plecanatide is currently in a phase IIb study for the treatment
of patients suffering from irritable bowel syndrome with
constipation (IBS-C). Synergy Pharma expects to enroll the last
patient for the study by year end and release top-line data from
this study in the first quarter of 2014.
We expect investor focus to remain on updates regarding the
development of the company's pipeline. The successful development
and commercialization of the candidates would be a major positive
for Synergy Pharma.
However, the constipation market already includes
Synergy Pharma currently carries a Zacks Rank #3 (Hold). Right
) looks attractive with a Zacks Rank #1 (Strong Buy).